Chordate and Nanos Medical concludes Joint venture for China

Chordate Medical Holding AB (publ) ("Chordate") has, through its subsidiary Chordate Medical AB, signed an agreement of co-ownership of a newly registered Shanghai-based company in a Joint venture with Nanos Medical (Shanghai) Limited (' Nanos Medical '), primarily concerning the Chinese market. Nanos Medical invests MUSD 1.5 for about 67 percent ownership of the joint venture, while Chordate for its share of 33 percent adds their eight Chinese patents. The parties assess that sales can commence within 3 years in the Chinese market.

" Chordate and Nanos Medical represents together a strong combination of patented technology and efficient market access competence. This long-term cooperation gives us a central position in the Chinese ear-nose-throat market (ENT), and freedom for Chordate to be focusing its own resources on building further market presence, primarily in the EU. Being able to take such a big and important step early in our international commercialization, is something that I deem as extremely valuable to our company," says Anders Weilandt, CEO of Chordate.

"Nanos Medical has ENT and cardio-vascular technology as the primary focus. Chordate's treatment method and product system is now added to our strong offer within ENT, where we already have well established channels. Initially we shall successfully manage the product registration process of Chordate's product in China, and parallel to that secure the production capacity, as well as important customer contacts to ensure a quick market introduction. We are looking forward to make this cooperation with Chordate into a great success for both parties, and for our respective shareholders," says Nanos Medical's CEO, Terry Cui.

Kista-Shanghai, 24 May 2018

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Phone: +46 (0) 733 87 42 77

Terry Cui, CEO
terry@nanosmedical.com 
Phone: +86 (0) 21- 60433667

Information:
This information is such information that Chordate Medical Holding AB (publ) is required to disclose under the EU market abuse regulation. The information was provided, through the contact person above, for publication on the 24 May 2018 At. 15:45 CET.

to the Editors

Om Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new treatment method for chronic nasal congestion through nerve stimulation. The company sells its product system including treatments through its own sales organization and through distributors to clinics and hospitals, which in turn treats patients. Read more at www.chordate.com. Mangold fondkommission AB, Tel.nr. + 46 8 5030 1550, is the company's mentor and as liquidity provider at NGM Nordic MTF.

Om Nanos Medical
Nanos Medical develops, manufactures and markets medical devices. Nanos Medical is headquartered in Shanghai and has an ISO13485 Certified and GMP compliant manufacturing plant in Suzhou, Jiangsu Province in China. Nanos Medical also serves as an important platform for licensing innovative technologies and products on a global basis and commercialises these in China and other emerging markets.

2018-08-14
Regulatorisk

Kista, 14 augusti 2018. Severn Healthcare Technologies Ltd. ("Severn") och Chordate Medical Holding AB (publ) har genom Dotterbolaget Chordate Medical AB ("Chordate") träffat ett exklusivt distributionsavtal för försäljning av Chordates produkter i Storbritannien och Irland. Severn är ett av Storbritanniens mest snabbväxande medicintekniska distributörsbolag med tydligt fokus på Öron-Näsa-Halsmarknaden ("ÖNH").

2018-08-14
Regulatory

Kista, August 14, 2018. Severn Healthcare Technologies Ltd. ("Severn") and Chordate Medical Holding AB (publ) have signed an exclusive distribution agreement for Chordate's products in UK and Ireland through the subsidiary Chordate Medical AB ("Chordate"). Severn is one of UK's fastest-growing medical technology distributors, with focus on the Ear-Nose-Throat ("ENT") Market.

2018-07-12
Regulatorisk

Chordate Medical Holding AB (publ) genomförde tidigare i år en företrädesemission samt en riktad kvittningsemission där aktieägare och investerare kunde teckna units. Emissionerna registrerades hos Bolagsverket i juli. Varje unit består av en nyemitterad aktie och en teckningsoption. Totalt emitterades 11 520 845 units i emissionerna (tidigare kommunicerades 9 853 918 units), och därmed finns lika många teckningsoptioner.

2018-06-07
Regulatorisk

Chordate Medical Holding AB (publ) har i maj/juni 2018 genomfört en företrädesemission vilket tillför bolaget ca 19 MSEK före emissionskostnader och kvittningar.

2018-05-30
Regulatorisk
Med anledning av Chordate Medical Holding ABs (publ) ("Chordate") avtal om att bilda ett joint venture med Nanos Medical (Shanghai) Limited ("Nanos Medical") avseende främst den kinesiska marknaden utvecklar Chordates VD Anders Weilandt avtalets innebörd och potential i följande videointervju.
2018-05-28
Regulatorisk

Chordate Medical Holding AB (publ) ("Chordate") har tecknat avtal om att bilda ett joint venture med Nanos Medical (Shanghai) Limited ("Nanos Medical"), avseende främst Kina. Med anledning av att detta avtal som Chordate anser vara strategiskt viktigt och som rimligen väsentligt kommer påverka verksamheten positivt över tid, förlängs den nu pågående teckningsperioden fram till 1 juni 2018.

2018-05-25
Regulatorisk

Sammanfattning av kvartalet januari-mars 2018

  • Nettoomsättningen uppgick till 194 369 SEK (272 585)
  • Kassaflöde från den löpande verksamheten var -3 880 599 SEK (-8 442 419)
  • Resultat efter finansiella poster var SEK -6 855 583 (-4 409 503)
  • Resultat efter skatt var SEK -6 855 583 (-4 409 503)
  • Resultat per aktie var SEK -1,89 (-1,66)
2018-05-24
Regulatorisk

Chordate Medical Holding AB (publ) ("Chordate") har genom sitt dotterbolag Chordate Medical AB tecknat avtal om samägande av ett nyregistrerat Shanghai-baserade bolag i joint venture med Nanos Medical (Shanghai) Limited ("Nanos Medical"), avseende främst den kinesiska marknaden. Nanos Medical investerar MUSD 1,5 ca 67 procent av det samägda bolaget medan Chordate för sin andel om 33 procent tillför en sina åtta kinesiska patent. Bedömningen är att försäljning på den kinesiska marknaden kan påbörjas inom 3 år.

2018-05-24
Regulatory

Chordate Medical Holding AB (publ) ("Chordate") has, through its subsidiary Chordate Medical AB, signed an agreement of co-ownership of a newly registered Shanghai-based company in a Joint venture with Nanos Medical (Shanghai) Limited (' Nanos Medical '), primarily concerning the Chinese market. Nanos Medical invests MUSD 1.5 for about 67 percent ownership of the joint venture, while Chordate for its share of 33 percent adds their eight Chinese patents. The parties assess that sales can commence within 3 years in the Chinese market.

2018-05-22
Regulatorisk

Chordate Medical Holding AB (Publ) meddelar att man kommer att delta på G&W Småbolagsfrukost på IVA konferenscenter, Grev Turegatan 16 i Stockholm den 24 maj, kl. 09.00 och presenterar senaste utvecklingen och framtid i bolaget.

2018-05-22
Regulatorisk

Chordate Medical Holding AB (Publ) meddelar att man kommer att delta på G&W Småbolagsfrukost på IVA konferenscenter, Grev Turegatan 16 i Stockholm den 24 maj, kl. 12.00 och presenterar senaste utvecklingen och framtid i bolaget.

<<
1
...
3
4
5
6
...
9
>>

Prenumerera

Pressmeddelanden och rapporter via E-post.

Investor relations